Introduction Complications due to unsafe abortions are an important cause of morbidity and mortality in many sub-Saharan African countries. We aimed to characterise abortion-related complication severity, describe their management, and to report women’s experience of abortion care in Africa.
Methods A cross-sectional study was implemented in 210 health facilities across 11 sub-Saharan African countries. Data were collected on women’s characteristics, clinical information and women’s experience of abortion care (using the audio computer-assisted self-interviewing (ACASI) system). Severity of abortion complications were organised in five hierarchical mutually exclusive categories based on indicators present at assessment. Descriptive bivariate analysis was performed for women’s characteristics, management of complications and reported experiences of abortion care by severity. Generalised linear estimation models were used to assess the association between women’s characteristics and severity of complications.
Results There were 13 657 women who had an abortion-related complication: 323 (2.4%) women were classified with severe maternal outcomes, 957 (7.0%) had potentially life-threatening complications, 7953 (58.2%) had moderate complications and 4424 (32.4%) women had mild complications. Women who were single, multiparous, presenting ≥13 weeks of gestational age and where expulsion of products of conception occurred prior to arrival to facility were more likely to experience severe complications. For management, the commonly used mechanical methods of uterine evacuation were manual vacuum aspiration (76.9%), followed by dilation and curettage (D&C) (20.1%). Most frequently used uterotonics were oxytocin (50∙9%) and misoprostol (22.7%). Via ACASI, 602 (19.5%) women reported having an induced abortion. Of those, misoprostol was the most commonly reported method (54.3%).
Conclusion There is a critical need to increase access to and quality of evidence-based safe abortion, postabortion care and to improve understanding around women’s experiences of abortion care.
- cross-sectional survey
This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.
Statistics from Altmetric.com
What is already known?
According to the most recent estimates, unsafe abortions account for half of all abortions globally, with the majority of the abortion-related deaths occurring in Africa.
As a result, serious complications arise from unsafe abortions; however, given the lack of use of standard definitions, identification criteria and standardised measurement tools, as well as variations in estimations of the complications, there is limited evidence on the morbidity associated with abortion-related complications.
As stated at the 1994 International Conference on Population and Development (ICPD) and reiterated in 2019 at ICPD25, it is imperative to reduce abortion-related complications as it is an integral part of sexual and reproductive health and key to reducing maternal mortality.
What are the new findings?
This is one of the few global studies to provide data on abortion-related complications, collecting data across 210 health facilities in 11 sub-Saharan African countries using a standardised tool.
This study provides insights on the burden and management of abortion-related complications in health facilities using a hierarchal severity gradient, according to sociodemographic, obstetric and clinical characteristics.
Furthermore, this is the first WHO multicountry survey to explore women’s experience of care during postabortion care.
What do the new findings imply?
Abortion-related complications are an important underlying and contributing cause of maternal morbidity and mortality as unsafe abortion remains a critical public health issue in sub-Saharan Africa.
Further efforts are required to increase access to safe abortion and contraception services and improving the quality of postabortion care including the implementation of evidence-based practices and better understanding around women’s experiences of abortion care.
According to the most recent estimates, between 2015 and 2019, 73.3 million abortions occurred worldwide each year, with 8 million abortions occurring in sub-Saharan Africa.1 2 Globally, it has been estimated that 45.1% (95% CI 40.6 to 50.1) abortions are unsafe,1 2 with75.6% (95% CI 66.4 to 81·4) of abortions occurring in the Africa region classified as unsafe. In the region, almost all unsafe abortions were categorised as least safe, the lowest ranking in the three-tiered approach, defined as abortion provision by untrained individuals using a dangerous method.1 The highest proportion of least safe abortions occurred in middle Africa, followed by West Africa and East Africa. To inform better policies and practices related to safe abortion and postabortion care, WHO has been developing guidelines on management of abortion, the role of healthcare workers including the women herself in the case of medical abortion as well as management of abortion-related complications.3–5 WHO has recently updated its recommendations, synthesising the latest evidence, to respond to the increased use of medical abortion globally.6
Severe abortion-related complications arise from least safe abortions with almost a third (31.3%, 95% CI 21.0 to 41.9) in legally restrictive settings.1 These complications are an important and preventable cause of maternal mortality.7 Between 2008 and 2013, it was estimated that 9.6% (95% CI 5.1 to 17.2) of maternal deaths are attributable to abortion-related causes in sub-Saharan Africa.7 Studies that look at the morbidity from abortion globally and in Africa, using a standard measurement of severity and management of these complications are limited and varied.8–13 Current studies offer quantification of the abortion-related complications, but they often do not investigate the gradient or severity of these complications and, do not assess the quality of the care provided.
Since the initial launch and 25th anniversary of the International Conference on Population and Development, it has been stated that abortion care is an integral part of sexual and reproductive health.14 15 However, the provision of safe abortion and postabortion care in many countries may be hindered by legally restrictive abortion laws and policies, weak health systems, socioeconomic conditions, the availability of safe abortion services and the stigma surrounding abortion. Capturing accurate information on abortion care can be challenging in such restricted settings. Furthermore, the Lancet Commission on High-Quality Health Systems highlighted that stigmatised conditions such as abortion make individuals more susceptible and vulnerable to poor-quality care.16 Women’s experiences of care should be an integral component of high-quality abortion care.17
Previous WHO multicountry survey research network studies on maternal and newborn health have been limited in terms of the insight they provided on abortion-related complications.18–20 To inform policy and programmatic actions to improve quality of abortion-related care in facilities, in the multicountry survey on abortion-related morbidity (MCS-A), we evaluated the severity of abortion-related complications and the management of these complications, and explored the experience of abortion care reported by women across 11 sub-Saharan African countries.21
Study design and participants
The study protocol of the WHO MCS-A study has been published previously, describing the methodology of the cross-sectional study with prospective data collection across health facilities.21 This analysis focuses on the primary findings from the sub-Saharan Africa region. Briefly, after a multistage sampling, the 11 participating countries were identified (Benin, Burkina Faso, Chad, Democratic Republic of the Congo (DRC), Ghana, Kenya, Malawi, Mozambique, Niger, Nigeria, Uganda), followed by provinces and facilities in each country.22
Health facilities were only eligible if they fulfilled the following characteristics: >1000 deliveries per year, a gynaecology ward and surgical capability (defined as providing the signal functions for comprehensive emergency obstetric care, which includes removal of retained products and surgical capability23 and, if available, abortion provision and/or postabortion care. To ensure each facility could contribute sufficient data to the study during the 3-month data collection period, facilities reporting <10 postabortion care patients on average over a month in the facility assessment form were excluded. In each country, data collection took place over a 3-month period between February 2017 and April 2018.
All women presenting to the participating facilities with signs and symptoms or death at discharge from abortion-related complications or early pregnancy loss (including ectopic and molar pregnancies) were included. Pregnant women with a diagnosis of threatened abortion, defined as vaginal bleeding with a closed cervix were excluded.24 The criterion of all women presenting to the facilities rather than admission to the facility was used to avoid exclusion of those women who seek care in the facilities for mild complications. Women with abortion-related complications who were admitted or had a prolonged hospital stay (>24 hours), able and were willing to consent were eligible to participate in the exit survey and convenience sampling was used to invite eligible women to participate in the exit survey based on the workload of data collectors and time of day in the study facility.
A hospital administrator or a healthcare provider responsible for the gynaecology and obstetrics wards at each identified facility completed the facility assessment form that collected information on availability of services and resources. For the main survey, 1-week training sessions were conducted with research assistants at the facility and country level on the objectives of the study, data collection procedures, practice sessions with the tools as well as highlighting ethical, safety and confidentiality considerations. Techniques of information gathering on this sensitive and highly stigmatised topic using the medical records were also conducted during the training session and data collectors had access to facility coordinators and principal investigators for continuous support. Based on the eligibility criteria, research assistants at each facility reviewed and abstracted information from women’s medical records that included sociodemographic data, clinical information, obstetrics characteristics, signs and symptoms due to abortion-related complication, medical procedures, clinical outcomes and vital status at discharge to identify eligible women. Abstracted medical records data were transcribed into paper-based case report forms and entered into a web-based electronic data capture system developed by the Centro Rosario de Estudios Perinatales (Rosario, Argentina) for the study. Data entry was performed at the health facility or at a central level, dependent on logistics and available infrastructure. For the exit survey, data were collected on tablets using the audio computer-assisted self-interviewing (ACASI) system developed by Tufts University. The system allowed participants to respond to the exit survey at a private location with a focus on maintaining participant confidentiality. Data collected in the exit survey consisted of abortion safety characteristics (method used, provider, setting) prior to coming to the facility, and women’s experience of abortion care related to effective communication, respect and dignity and emotional support during their time in the facility. The women who participated in the exit survey were compensated for their time by approximately US$2 worth of mobile phone airtime. Data managers in Argentina continuously monitored the study data flow and data quality by use of validation procedures and progress reports for all countries. Data inconsistencies were identified and corrected by contacting the study principal investigators as they emerged. These procedures have been used in previous multicentre studies.25
Description of measures
Based on indicators present at time of hospital admission including clinical, laboratory and management-based markers, abortion-related complications were classified into five hierarchical and mutually exclusive categories based on severity: (1) deaths, (2) near miss, (3) potentially life-threatening complications, (4) moderate complications and (5) mild complications (figure 1).
Based on WHO criteria for near miss, women who died or identified as a near-miss case were classified as a severe maternal outcome.26 Women presenting with severe haemorrhage, severe systemic infection or suspected uterine perforation were classified based on WHO’s criteria for potentially life-threatening conditions.26 Moderate complications included bleeding, suspected intra-abdominal injury and infection. Mild complications included any abnormal signs from initial physical examination (vital signs, appearance, mental status, abdominal examination, gynaecological examination). Death was based on woman’s status at discharge. Online supplemental file 4 includes the identification criteria used for each severity category in detail and, online supplemental file 1 includes information on timing of abortion-related complications based on facility admission.
Gestational age at presentation was grouped as <13 weeks, ≥13 weeks or undetermined weeks (online supplemental file 1). Clinical management of abortion-related complications was categorised as medically managed by uterotonics only, by uterine evacuation only or both methods. Uterotonics use was further divided into: misoprostol alone, oxytocin alone, ergometrine only and their combinations. Uterine evacuation was further examined by type of procedure: manual vacuum aspiration (MVA), dilation and curettage (D&C) and both.
Patient and public involvement
Development of the protocol used evidence from qualitative research exploring women’s experiences with abortion care. The been published, the results will be disseminated for professional and non-professional audiences in participating countries.
Descriptive bivariate analysis was performed for national level and facility level characteristics (online supplemental file 1), as well as sociodemographic, obstetrics and clinical management characteristics by severity of abortion-related complications. The χ2 test was used to compare proportions of descriptive characteristics across severity categories. Severity of abortion-related complications is presented across countries as ratios calculated based on the prevalence of each category of complication per 1000 women with complications.
Descriptive analysis was also performed to evaluate the methods used, information received and help sought to end pregnancy for self-reported data collected in the exit interview via the ACASI platform. Experience of abortion care during facility stay was assessed by comparing responses across severity of abortion-related complications using χ2 test.
Regression methods were used to evaluate women’s characteristics potentially associated with the outcome of abortion-related complication severity. Generalised linear models, adjusting for facility clustering effect and differences across countries, were fitted to estimate the odds of severe maternal outcomes, potentially life-threatening complications and, moderate complications for women’s characteristics. The independent variables were categorical variables including sociodemographic characteristics (age, marital status, education, gainful occupation) and, obstetric characteristics (prior pregnancies, gestational age and expulsion of products of conception before arrival to the health facility).
Data analysis was conducted using SAS (V.9.4, Cary, North Carolina, USA).
We collected data on 15 671 women attending 210 facilities in 11 sub-Saharan African countries (figure 1); 124/210 (59∙1%) of the facilities were secondary level facilities and most included received care in urban facilities (9,839, 72%). Details on facility characteristics included can be found in the online supplemental file 3.
A total of 73 women were excluded, of which 9 were excluded from these analyses as they did not have corresponding facility records and 64 had ACASI data only without corresponding individual records. A further 1815 (13∙2%) women were excluded because they had complications related to molar and ectopic pregnancies (n=1782) or they did not have a final diagnosis (n=33). For 126 (0∙9%) women, there was insufficient information collected for severity to be determined and these women were excluded from the analyses. The final sample included 13 657 medical records and the analysis of these records focused on women with abortion-related complications.
Based on the inclusion criteria and available data on admission and discharge dates, 65.6% (8931/13614) of the women with abortion-related complications were eligible for ACASI exit interview. Of those, a total of 3091/8931 (34∙6%) women were recruited and participated in the ACASI exit interview.
Table 1 compares national, facility, demographic and obstetric characteristics of women, according to complication severity. Nearly half the sample, 6493 (47∙6%) were from countries where both misoprostol and mifepristone were registered for medical abortion, and 7435 women (54∙4%) were from countries which do not have any national guidelines on abortion (induced abortion or postabortion care). Online supplemental file 2 describes the legal status of abortion in the study countries, with the majority of countries having a law that allows or permits abortion only on one or more legal grounds.27
Severity of abortion-related complications
Of all the women who had abortion-related complications (n=13 657), 264 (1∙9%) women were classified as near-miss cases, 957 (7∙0%) had potentially life-threatening complications, 7953 (58∙2%) had moderate complications and 4424 (32∙4%) women had mild complications. In addition, there were 59 (0∙4%) deaths due to abortion-related complications. Abortion-related deaths and women with near-miss complications were grouped as severe maternal outcomes, representing a total of 323 women (2∙6%) (figure 1). Among women with near miss, the most common organ dysfunction identified was cardiovascular (165/264, 62∙5%). Among potentially life-threatening, moderate and mild complications, the most commonly identified complications were severe haemorrhage (703/957, 73∙2%), heavy bright bleeding (7656/7953, 96∙3%) and vaginal bleeding (3470/4424, 78∙4%) (online supplemental file 4).
Among women presenting to facilities with an abortion-related complication (n=13 657), they were between the ages of 20 and 29 years, and most were married or cohabitating (77∙4%) and reported secondary education or above (54∙3%). Less than half of the women were gainfully employed. According to their obstetric history, most women had a previous pregnancy (91∙5%) and many (64∙1%) did not have any previous abortions. Significant differences were observed across severity categories for marital status, education, gainful occupation and timing of expulsion of products of conception.
Figure 2 describes the severity of complications across countries per 1000 women with complications. Severe maternal outcomes ranged from 5 per 1000 women in Niger to 48 per 1000 women in Nigeria. Potentially life-threatening complications ranged from 14 per 1000 women in Niger to 105 per 1000 women in Uganda. Moderate complications ranged from 395 per 1000 women in Malawi to 795 per 1000 women in Benin, and the mild complications ranged from 91 per 1000 women in Benin to 536 per 1000 women in Niger.
Table 2 presents generalised linear models evaluating women’s characteristics associated with severe maternal outcomes, potentially life-threatening and moderate abortion-related complications compared with mild complications, adjusting for country, age, education, occupation, prior pregnancy and gestational age and timing of expulsion of products of conception. In the adjusted model, being single (adjusted OR (aOR): 3∙4 (95% CI 2∙2 to 5∙3)), having prior pregnancies (aOR: 2∙1 (95% CI 1∙3 to 3∙5)) and presenting at later gestational ages (≥13 weeks) (aOR: 3∙5 (95% CI 2∙3 to 5∙4)) were positively associated with experiencing severe maternal outcomes compared with women with mild complications. Furthermore, our model shows that women who had expulsion of products of conception prior to arrival to the health facility were twice (aOR: 2∙3 (95% CI 1∙6 to 3∙4)) as likely to experience severe maternal outcomes.
When women with potentially life-threatening complications were compared with mild complications (adjusting for country, age, education, occupation, prior pregnancy and gestational age and timing of expulsion of products of conception), similar pattern to severe maternal outcomes were observed (table 2). In the adjusted model, being single (aOR: 1∙5 (95% CI 1∙2 to 1∙8)), having prior pregnancies (aOR: 1∙2 (95% CI 1∙0 to 1∙5)), presenting at later gestational ages (≥13 weeks) (aOR: 1∙7 (95% CI 1∙3 to 2∙2)) and expulsion of products of conception prior to arrival to the health facility (aOR: 1∙8 (95% CI 1∙4 to 2∙2)) are positively associated with experiencing potentially life-threatening complications. Women with no or primary education were more likely to experience potentially life-threatening complications: 1∙5 (95% CI 1∙2 to 1∙9), 1∙4 (95% CI 1∙2 to 1∙7). Finally, women with moderate complications had no significant associations, except slightly elevated odds with primary education 1∙1 (95% CI 1∙0 to 1∙3), compared with mild complications.
Management of abortion-related complications
As shown in table 3, approximately 50% of the women received both uterotonics and underwent uterine evacuation for management of abortion-related complications across all severity categories. For other management types, 16∙7% of women received uterotonics only and 27∙6% of women underwent uterine evacuation only. Across severity categories, for mild complications, uterine evacuation was performed more commonly (35∙6%) than for the other groups. Women with potentially life-threatening (56∙7%) or moderate complications (52∙5%) more commonly received both uterotonics and uterine evacuation compared with women with mild complications (44∙2%) and severe maternal outcomes (35∙3%).
Table 4 details the type of management for our study sample. Overall, 66∙4% of women received uterotonics, and among those the most commonly used was oxytocin (50∙9%), followed by misoprostol (22∙7%). Uterine evacuation was performed in 77∙3% women, the most common method used was MVA (in 76∙9% women), and its use was most frequent in the moderate cases (79∙3%). Following MVA, D&C was used among 20∙1% of women. 8∙1% of the women received blood products and their use was mostly among the severe maternal outcomes (55∙4%) and potentially life-threatening complications (48∙2%). A total of 121 women underwent major surgeries. The most common were exploratory laparotomy, (76%) and hysterectomy (21∙5%). Almost 9 out of 10 women received antibiotics for prophylaxis of treatment. Among the small number of women (77, 0∙6%) who were admitted to intensive care unit, the majority were those with severe maternal outcomes.
Women’s self-reported experiences of abortion care via ACASI exit survey
Distribution of sociodemographic and obstetric characteristics of the women who participated in the ACASI exit interview were not significantly different from the overall study population (except for gestational age) (online supplemental file 5). Of the 3091 women who undertook ACASI exit interview, only 602 women (19∙5%) reported having used one method or more to end their pregnancy. The most commonly reported methods to end the pregnancy were: misoprostol (54∙3%), other medicines either orally or vaginally (40∙5%) and procedures that cleared out contents from the uterus (38∙7%). Furthermore, 18∙7% reported using of herbs, antimalarial drugs, bleach, gasoline and detergents and 14∙3% reported using traditional abdominal massage.
Of the 602 women who reported induced abortion, 241 (39∙9%) reported that they did not receive any information about the method used to end pregnancy. For the rest, the most commonly reported sources of information were friends (33∙4%), husband /partner/boyfriend (28∙9%), followed by healthcare providers (25∙1% medical doctor, 24∙5% pharmacist, 23∙4% nurse/midwife). More than 1 in 10 women reported getting information through internet or social media, whereas only 6∙8% reported radio or TV as a source of information (figure 3). In terms of receiving assistance from someone to end their pregnancy, 261 (42∙7%) of the women did not get any help. The most commonly reported assistance was from healthcare providers (23∙4% medical doctors, 21∙6% nurse/midwifes, 16∙8% pharmacist). Of note, more than one in five women reported being assisted by a friend (figure 3).
Table 5 presents experience of abortion care during facility stay as reported by women. Overall, 19∙1% of the women stated that they were not given explanations regarding their care and treatment. One out of three women reported that they were not able to ask questions during their examination and treatment. Overall, 18∙5% of women felt their choices and preferences were not followed during hospital stay and this differed significantly across severity categories. Women who reported not being spoken to nicely during their stay ranged between 6∙9% among women with potentially life-threatening complications and 9∙8% among women with moderate complications; 13∙2% of women reported not having received pain medications during their stay ranging from 9∙9% among women with severe complications to 14∙6% among women with moderate complications.
Our study quantified the health burden experienced by women presenting with abortion-related complications in 11 sub-Saharan African countries. We used a gradient to examine and report on the severity of and management of abortion-related complications across 13 657 women, 210 health facilities and subsample of women-reported experiences. Of all women with abortion-related complications, approximately 2.3% were identified as severe maternal outcomes, 7.0% potentially life-threatening complications, 58% moderate and 32% mild complications. The proportion of women presenting with severe maternal outcomes and potentially life-threatening complications indicates that unsafe abortion continues to pose a major public health challenge in Africa. The prevalence of these severe complications varies across countries, compared with other findings, illustrating the issues with comparability due to lack of a standardised approach in measurement of abortion-related complications. Globally, at least 9% of abortion-related complications in health facilities were identified as a near-miss event,13 while studies from Africa report varying prevalence of severe abortion-related complications. These studies have used different criteria, ranging from Rees et al28 to expanded WHO near-miss criteria,29 to define and measure complication severity, leading to different estimations as seen from various studies in DRC (16%), Kenya (37%), Malawi (21%), Zambia (16%) and Zimbabwe (19%).8 9 11 30 31 Our results underline the importance of using standardised definitions including the application of WHO’s near-miss criteria29 to ensure comparability when quantifying the burden of abortion-related complications as well as measuring the progress globally and in the context of Africa.12 13
Our results show that 9 out of 10 women who seek care in the facilities have moderate or mild complications (most commonly with some form of vaginal bleeding), which may reflect the changing tide of abortion due to medical abortion. After medical abortion use, WHO recommendations on medical abortion highlights that vaginal bleeding for 2 weeks is normal and serious side effects including adverse events are rarely reported with the appropriate medical abortion regimen.6 We were not able to discern whether vaginal bleeding was due to medical abortion use prior to seeking care in facilities. A plausible explanation is that women presenting with mild complications may have been experiencing this common side effect of medical abortion use which highlights the importance of access to quality information and services regarding medical abortion.
Severe abortion-related complications were associated with being single, having a prior pregnancy and late gestational age (≥13 weeks), with over a twofold increase in odds among severe maternal outcomes. These findings are consistent with other studies that found increased likelihood of severe abortion-related complications due to similar characteristics.8 11 31 32 Abortion remains a stigmatised issue in Africa creating further inequities and vulnerabilities for women based on their socioeconomic characteristics, such as marital status, contributing to severe complications.10 Severe abortion-related complications were also associated with expulsion of products of conception (POC) prior to arrival to the facility. This may be attributable to a number of possible gaps in the information channels regarding the recommended medical abortion dosage, on when to seek postabortion care, side effects and symptoms of possible complications.10 33–35 Women might also not be aware of the services available, may fear stigma and mistreatment and use methods which are considered unsafe. According to a systematic review, awareness and knowledge of the abortion laws and policy environment among women was limited, even in countries where the laws were liberal, hindering women from accessing available services.36
In terms of management of abortion-related complications at the health facility, approximately half of the abortion-related complications were treated with both uterotonics and uterine evacuation. The use of both uterotonic and uterine evacuation may be a reflection of overmedicalization due to possible provider preference and practice rather than evidence-based recommendations.37 This is particularly important among mild complications presenting with vaginal bleeding that may have been due to medical abortion use prior to the facility. The management of abortion-related complications using safe and low-cost technologies, such as MVA, which is the recommended method of uterine evacuation regardless of severity,3 is on the rise across countries in our study; however, the use of non-recommended and unsafe methods such as D&C still persists. This may be due to lack of resources (eg, equipment and supplies)38 and/or training, which might lead providers to use outdated methods like D&C.10 12 39 Furthermore, half of our cases received oxytocin as the most common method of uterotonics, rather than misoprostol, which is recommended to manage abortion-related complications.6 40 The less frequent use of misoprostol may be due to lack of availability, familiarity, training and guidelines as well as providers’ perceptions on misoprostol being a less effective and safe method of postabortion care.12 40 The inequities in the provision of good quality care highlight the need to strengthen the adoption and implementation of evidence-based recommendations for the provision of postabortion care.4 41
Of the participating women in the ACASI exit survey, one in two reported induced abortion with the most commonly used method being misoprostol, whereas one in five still reported using dangerous methods such as antimalarial drugs, or insertion of something into the vagina. This supports the trends observed that medical abortion is becoming more commonly used among women and possibly contributing to the reduction in the burden of severe complications.1 Furthermore, our results indicate that a small but significant proportion of women accessed information through social media and internet. This suggests that these channels may be used for informing women about safe abortion options and postabortion care (in areas where internet access is available) paving the way for telemedicine to be adopted given the evidence that it is becoming more acceptable to women and providers.42 Reducing the burden of both severe and mild complications among women can be improved through implementation of evidence-based practices which include provision of accurate information and resources for women seeking medical abortion outside of healthcare facilities.3 33 34 43 These approaches might also be applicable to better inform women about what to expect after medical abortion and when to seek care from facilities, reducing the burden on women and health systems alike.
For women’s experiences of postabortion care, among those participating in the exit survey, one in five women felt that their choices and preferences were not followed during care and the same proportion did not receive explanations regarding their care. Evidence shows that mistreatment during childbirth in the facility may be a significant barrier to women’s decision to seek care.44 Furthermore, provider perceptions on abortion care and workload can negatively impact provider-patient interaction, timeliness and quality of care.12 Globally, there is growing interest in measuring person-centred reproductive healthcare including abortion care, contraception and maternity care.38 45–47 While the evidence around measuring women’s experiences seeking abortion-related care, in particular, is limited, research efforts are increasing to support the development of measurement tools.38
Strengths and limitations
We sought to use a standardised approach to identify abortion-related complications across 210 facilities in 11 countries. The large sample size and number of participating facilities enables generalisability of results to facilities with similar outcomes and geographical areas similar to those included in our study, and other sub-Saharan African countries (lusophone, francophone, anglophone). Our results are not representative of the population and despite the implementation of standardised definitions for abortion-related complications, a few data collection issues linked to the quality of the medical records (eg, poor record keeping, especially on abortion) may have led to underestimation and/or misclassification of severity across countries. Furthermore, depending on the countries and the context, including the abortion rate, the number percentage of women experiencing a complication after abortion and further seeking care at the facilities might vary. Due to the sensitive nature of the topic in all the study countries, we did not differentiate between induced and spontaneous abortion during data collection, and it should be noted that induced abortion-related complications may be more severe compared with spontaneous abortions.13 Our study is based on a cross-sectional survey across facilities and limited to the women who present at these facilities for abortion-related complications. The study also incorporated a confidential self-reported exit interview component to measure women’s experiences of abortion care (prior to coming and during their facility stay) using the ACASI software. ACASI was used given that it is well-suited for collecting data on sensitive data; however, women may have still under-reported induced abortion.
Unsafe abortion remains a critical public health issue in sub-Saharan African countries, causing significant morbidity for women and burden on health systems. Based on our results, future areas of work include using the standardised approach to quantify abortion-related complications in health facilities, implementing clinical management practices in line with evidence-based recommendations and conducting further research to develop measurement tools to report women’s experiences of abortion care. Delays in seeking care for abortion-related complications increases the risk of severe morbidity, therefore there is a need to strengthen provision of accurate information and services to reduce such delays. It is vital for countries to implement context-specific programmes to increase access to and quality of safe abortion and contraception services.
The WHO multicountry survey on abortion (MCS-A) is a research project implemented by WHO across a network of health facilities in Africa. The authors would like to thank the women who participated in this study. WHO is grateful to the extensive network of institutions and individuals who contributed to the project design and implementation, including researchers, study coordinators, data collectors, data clerks and other partners including the staff from the Ministries of Health and WHO offices. The authors would like to acknowledge the contribution and lifelong achievements of the coauthor Professor Bukola Fawole, who passed away prior to the publication of this article. All listed authors are members of the WHO MCS-A research group. The WHO MCS-A research group is grateful to Adama Baguiya, Josaphat Byamugisha, Liana Campodónico, Rachidatou Compaoré, Emídio Cumbane, Wasswa Damien, Atkure Defar Deghebo, Felicia Fasipe, Hugo Gamerro, Hailemichael Gebreselassie, Daniel Giordano, Philipp Guest, Christelle M. Boyi Hounsou, Lydie Kanhonou, Oluwatosin Lawal; Sarah de Masi, Miriam Nakalembe, Charlemagne Ouedraogo, Clementine Rossier, Joao Paulo Souza, Scott Sughrue, Anand Tamang, M. Christian Urlyss, Rajani Ved, Kwame Adu-Bonsaffoh for their contributions to the study.
Handling editor Seye Abimbola
Twitter @hediehmm, @1verofilippi, @Gulmezoglum, @bganatra, @otuncalp
ZQ and HM contributed equally.
Contributors CRK, ÖT, BG and AMG conceptualised the study and co-developed the study protocol with the research group. ZQ, HM and ÖT contributed to statistical analysis, interpretation of findings and drafted the manuscript on behalf of the WHO MCS-A study group. HM and SST performed statistical analysis. SK, SG, VF, PG, SST, FAB, LG, ATM, NI, SK, CRK, J-JW-M, KYM, CB, RA, TM, AMG and BG contributed to interpretation of findings and commented on previous versions of the manuscript. All members of the WHO MCS-A research group approved the final manuscript.
Funding This research was funded by the UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP), Department of Sexual and Reproductive Health and Research, World Health Organization, Geneva, Switzerland.
Competing interests None declared.
Patient consent for publication Not required.
Ethics approval This study was approved by the World Health Organization Ethical Review Committee (protocol: 0002699) and the World Health Organization Human Reproduction Programme (HRP) Review Panel on Research Projects. This study was also approved by in-country ethical committees in: Benin (le comité national d’éthique pour la recherche en santé); Burkina Faso (le ministère de la recherché scientifique et de l’innovation); Chad (ministère de l’enseignement supérieur et de la recherche scientifique); Democratic Republic of Congo (Ecole de santé publique comité d’éthique); Ghana (Ethical Review Committee of the Ghana Health Service; Ethical and Protocol Review Committee of the College of Health Sciences, University of Ghana); Kenya (University of Nairobi Ethics and Research Committee); Malawi (College of Medicine Research Ethics Committee (COMREC)); Mozambique (Comité Nacional de Bioetica para e saude, Ministerio de Saude); Nigeria (Federal Capital Territory Health Research Ethics Committee; Research Ethical Review Committee, Oyo State and State Health Research Ethics Committee of Ondo State) and Uganda (Mulago Hospital Research Committee; Uganda National Council for Science and Technology).
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement Data are available on request. The analytic study dataset from the 'WHO Multi-Country Survey on Abortion (MCS-A)' is deidentified and, archived through WHO/HRP’s electronic record management system. Data requests with an expression of interest in pursuing multicountry secondary analyses with a specific research question can be made to email@example.com and firstname.lastname@example.org. More information about the study is available here: https://gh.bmj.com/content/1/3/e000113.
Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.